financetom
Business
financetom
/
Business
/
Oilfield services provider SLB Q3 profit beats estimates driven by resilience in international markets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oilfield services provider SLB Q3 profit beats estimates driven by resilience in international markets
Oct 17, 2025 4:34 AM

Overview

* SLB Q3 revenue of $8.93 bln is in-line with analyst expectations

* Adjusted EPS of $0.69 beats consensus, reflecting operational strength

* Company completed acquisition of ChampionX, contributing $579 mln to Q3 revenue

Outlook

* SLB expects Q4 revenue growth driven by international markets and ChampionX integration

* Company anticipates international markets to lead future activity rebound

Result Drivers

* CHAMPIONX ACQUISITION - SLB's acquisition of ChampionX added $579 mln to Q3 revenue, significantly impacting Production Systems and Digital divisions

* DIGITAL GROWTH - Digital division saw revenue growth driven by Digital Operations and Exploration, aided by ChampionX and organic growth

* INTERNATIONAL RESILIENCE - SLB notes resilience in international markets, particularly in the Middle East and Asia, despite geopolitical challenges

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Meet $8.93 $8.93

Revenue bln bln (21

Analysts

)

Q3 Beat $0.69 $0.65

Adjusted (23

EPS Analysts

)

Q3 EPS $0.50

Q3 Net $739 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil related services and equipment peer group is "buy"

* Wall Street's median 12-month price target for Slb NV ( SLB ) is $43.00, about 23.4% above its October 16 closing price of $32.92

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Oct 16, 2025
08:07 AM EDT, 10/16/2025 (MT Newswires) -- Praxis Precision Medicines ( PRAX ) shares were 170% higher pre-bell Thursday after the company reported that its investigational drug ulixacaltamide in essential tremor helped improve patients' daily functioning in two late-stage trials. Cellectis ( CLLS ) stock was up 20% following a 1.4% loss in the previous session. JB Hunt Transport Services...
MGM Resorts to Sell MGM Northfield Park Operations to Clairvest for $546 Million
MGM Resorts to Sell MGM Northfield Park Operations to Clairvest for $546 Million
Oct 16, 2025
08:12 AM EDT, 10/16/2025 (MT Newswires) -- MGM Resorts International ( MGM ) said Thursday that it agreed to sell the operations of MGM Northfield Park racetrack and casino in Northfield, Ohio for $546 million in cash to private equity funds managed by Clairvest Group. When the deal closes, which is expected in H1 of 2026, MGM Resorts' ( MGM...
Critical Metals to raise $50 million PIPE financing
Critical Metals to raise $50 million PIPE financing
Oct 16, 2025
Oct 16 (Reuters) - Critical Metals said on Thursday it will raise $50 million through a private investment in public equity (PIPE) deal with an institutional investor to fund development of its Tanbreez rare earth deposit in Greenland. ...
C4 Therapeutics Prices $125 Million Underwritten Offering; Shares Fall Pre-Bell
C4 Therapeutics Prices $125 Million Underwritten Offering; Shares Fall Pre-Bell
Oct 16, 2025
08:09 AM EDT, 10/16/2025 (MT Newswires) -- C4 Therapeutics ( CCCC ) said Thursday it priced an underwritten offering of about 21.9 million common shares at $2.47 per share and pre-funded warrants to purchase up to 28.7 million common shares at $2.4699 per warrant. Each common share and pre-funded warrant are being sold together with class A and class B...
Copyright 2023-2026 - www.financetom.com All Rights Reserved